NASDAQ:ADRO - Aduro BioTech Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.15 -0.10 (-1.21 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$8.15
Today's Range$8.05 - $8.35
52-Week Range$5.82 - $14.05
Volume148,305 shs
Average Volume319,612 shs
Market Capitalization$645.59 million
P/E Ratio-5.74
Dividend YieldN/A
Beta2.1

About Aduro BioTech (NASDAQ:ADRO)

Aduro BioTech logoAduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer. Its products pipeline also comprises BION-1301, a B-select monoclonal antibody novel therapy for multiple myeloma; A PRoliferation-Inducing Ligand for the treatment of multiple myeloma, chronic lymphocytic leukemia, and colorectal carcinoma; CD27, a co-stimulatory receptor for the treatment of cancer; and CTLA-4 for the treatment of advanced melanoma and other cancers. The company's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neo antigens that are specific to an individual patient's tumor. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Janssen Biotech, Inc, and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.

Receive ADRO News and Ratings via Email

Sign-up to receive the latest news and ratings for ADRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADRO
CUSIPN/A
Phone510-848-4400

Debt

Debt-to-Equity RatioN/A
Current Ratio9.10
Quick Ratio9.10

Price-To-Earnings

Trailing P/E Ratio-5.74
Forward P/E Ratio-6.47
P/E GrowthN/A

Sales & Book Value

Annual Sales$17.24 million
Price / Sales37.22
Cash FlowN/A
Price / CashN/A
Book Value$2.50 per share
Price / Book3.26

Profitability

EPS (Most Recent Fiscal Year)($1.42)
Net Income$-91,860,000.00
Net Margins-455.58%
Return on Equity-39.00%
Return on Assets-20.59%

Miscellaneous

Employees162
Outstanding Shares78,730,000

Aduro BioTech (NASDAQ:ADRO) Frequently Asked Questions

What is Aduro BioTech's stock symbol?

Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."

How were Aduro BioTech's earnings last quarter?

Aduro BioTech Inc (NASDAQ:ADRO) announced its quarterly earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.07. The biotechnology company earned $6.63 million during the quarter, compared to analyst estimates of $3.88 million. Aduro BioTech had a negative return on equity of 39.00% and a negative net margin of 455.58%. View Aduro BioTech's Earnings History.

What price target have analysts set for ADRO?

7 Wall Street analysts have issued 12-month price targets for Aduro BioTech's shares. Their predictions range from $8.00 to $30.00. On average, they expect Aduro BioTech's stock price to reach $15.20 in the next twelve months. View Analyst Ratings for Aduro BioTech.

What are Wall Street analysts saying about Aduro BioTech stock?

Here are some recent quotes from research analysts about Aduro BioTech stock:
  • 1. According to Zacks Investment Research, "Aduro reported narrower-than-expected loss in the fourth quarter of 2017 while revenues missed estimates. The company has a broad, promising pipeline of novel immunotherapies under development for treatment of a variety of cancers. The company’s collaboration agreements with large pharma companies — Novartis and Johnson & Johnson — not only validate the company’s research platforms but also enhance its financial position, providing it with adequate funds. However, with no approved products in Aduro’s portfolio, the company heavily depends on funds generated from collaboration and license agreements, government grants as well as other payments for the development of its pipeline candidates. Thus, an inability to secure sufficient funding could hinder Aduro’s pipeline progress. Shares of the company have underperformed the industry in a year’s time." (3/7/2018)
  • 2. Cantor Fitzgerald analysts commented, "ADRO shares are trading up modestly on the disclosure of a $3 million milestone from MRK’s (Merck, NC) initiation of a Phase I trial with the anti- CD27 candidate." (3/5/2018)
  • 3. HC Wainwright analysts commented, "All Three Platforms Now Clinical Stage; We Have High Expectations for B-Select Platform B-select investment starts bearing clinical stage candidates. Aduro announced the expected initiation of a Phase 1/2 clinical trial with its anti-APRIL antibody, BION-1301. This two part, open-label study, is being conducted in relapsed or refractory multiple myeloma patients (at least three prior systemic therapies). Once the recommended Phase 2 dose is identified in part 1, patients are to be expanded at the selected dose with the primary endpoint of overall response rate. The APRIL/BCMA pathway was also a hot topic at the recent ASH conference as an encouraging new target against myeloma. A proliferation inducing ligand (APRIL) is one of the main high affinity ligands that binds and activates BCMA resulting in a pro-survival cell signal. APRIL is a member of the TNF family and is overexpressed in patients with multiple myeloma (MM)." (12/13/2017)

Who are some of Aduro BioTech's key competitors?

Who are Aduro BioTech's key executives?

Aduro BioTech's management team includes the folowing people:
  • Mr. Stephen T. Isaacs, Chairman, Pres & CEO (Age 69)
  • Mr. Blaine E. Templeman, Chief Legal Officer & Sec. (Age 52)
  • Dr. Natalie R. Sacks M.D., Chief Medical Officer (Age 53)
  • Ms. Jennifer Lew, Chief Financial Officer (Age 45)
  • Mr. Gregory W. Schafer, Consultant (Age 54)

When did Aduro BioTech IPO?

(ADRO) raised $119 million in an IPO on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Has Aduro BioTech been receiving favorable news coverage?

Media stories about ADRO stock have trended positive on Saturday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aduro BioTech earned a media sentiment score of 0.36 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 47.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Aduro BioTech's major shareholders?

Aduro BioTech's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.51%), Point72 Asset Management L.P. (2.16%), Baillie Gifford & Co. (2.10%), Harvard Management Co. Inc. (1.87%), Millennium Management LLC (1.63%) and BVF Inc. IL (1.03%). Company insiders that own Aduro BioTech stock include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Ross Haghighat, Stephen T Isaacs and Thomas W Dubensky. View Institutional Ownership Trends for Aduro BioTech.

Which institutional investors are selling Aduro BioTech stock?

ADRO stock was sold by a variety of institutional investors in the last quarter, including Harvard Management Co. Inc., Point72 Asset Management L.P., Oak Ridge Investments LLC, BlackRock Inc., Wells Fargo & Company MN and JPMorgan Chase & Co.. Company insiders that have sold Aduro BioTech company stock in the last year include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Stephen T Isaacs and Thomas W Dubensky. View Insider Buying and Selling for Aduro BioTech.

Which institutional investors are buying Aduro BioTech stock?

ADRO stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, BVF Inc. IL, Baillie Gifford & Co., Artal Group S.A., Barclays PLC, Foundry Partners LLC, Quantitative Systematic Strategies LLC and Alps Advisors Inc.. View Insider Buying and Selling for Aduro BioTech.

How do I buy shares of Aduro BioTech?

Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aduro BioTech's stock price today?

One share of ADRO stock can currently be purchased for approximately $8.15.

How big of a company is Aduro BioTech?

Aduro BioTech has a market capitalization of $645.59 million and generates $17.24 million in revenue each year. The biotechnology company earns $-91,860,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Aduro BioTech employs 162 workers across the globe.

How can I contact Aduro BioTech?

Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]


MarketBeat Community Rating for Aduro BioTech (ADRO)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  301 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  439
MarketBeat's community ratings are surveys of what our community members think about Aduro BioTech and other stocks. Vote "Outperform" if you believe ADRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADRO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aduro BioTech (NASDAQ:ADRO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Aduro BioTech in the last 12 months. Their average twelve-month price target is $15.20, suggesting that the stock has a possible upside of 86.50%. The high price target for ADRO is $30.00 and the low price target for ADRO is $8.00. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.753.003.00
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.20$15.6667$18.00$20.1667
Price Target Upside: 86.50% upside123.81% upside195.08% upside153.67% upside

Aduro BioTech (NASDAQ:ADRO) Consensus Price Target History

Price Target History for Aduro BioTech (NASDAQ:ADRO)

Aduro BioTech (NASDAQ:ADRO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2018HC WainwrightSet Price TargetBuy$10.00HighView Rating Details
3/5/2018Cantor FitzgeraldReiterated RatingBuy$15.00LowView Rating Details
3/2/2018Bank of AmericaLower Price TargetUnderperform ➝ Underperform$9.00 ➝ $8.00LowView Rating Details
3/2/2018Canaccord GenuityReiterated RatingBuyLowView Rating Details
12/13/2017OppenheimerLower Price TargetOutperform$15.00 ➝ $13.00HighView Rating Details
10/2/2017William BlairReiterated RatingOutperformHighView Rating Details
7/18/2017CowenInitiated CoverageOutperformLowView Rating Details
5/1/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$18.00LowView Rating Details
3/7/2017FBR & CoReiterated RatingBuy$23.00N/AView Rating Details
3/7/2017Roth CapitalReiterated RatingBuy$17.00N/AView Rating Details
10/24/2016Leerink SwannSet Price TargetBuy$14.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Aduro BioTech (NASDAQ:ADRO) Earnings History and Estimates Chart

Earnings by Quarter for Aduro BioTech (NASDAQ:ADRO)

Aduro BioTech (NASDAQ:ADRO) Earnings Estimates

2018 EPS Consensus Estimate: ($1.14)
2019 EPS Consensus Estimate: ($1.51)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.41)($0.24)($0.31)
Q2 20183($0.33)($0.19)($0.27)
Q3 20183($0.34)($0.20)($0.28)
Q4 20183($0.33)($0.21)($0.28)
Q1 20191($0.35)($0.35)($0.35)
Q2 20191($0.37)($0.37)($0.37)
Q3 20191($0.38)($0.38)($0.38)
Q4 20191($0.41)($0.41)($0.41)

Aduro BioTech (NASDAQ ADRO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018Q1 2018($0.35)($0.2760)$3.88 million$6.63 millionViewN/AView Earnings Details
3/1/2018Q4 2017($0.36)($0.35)$4.32 million$3.76 millionViewN/AView Earnings Details
10/31/2017Q3 2017($0.30)($0.33)$4.04 million$3.79 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.25)($0.27)$3.98 million$5.90 millionViewN/AView Earnings Details
5/2/2017Q1 2017($0.3880)($0.32)$3.74 million$3.77 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.40)($0.4390)$3.83 million$3.88 millionViewN/AView Earnings Details
11/2/2016Q3 2016($0.45)($0.54)$3.99 million$3.79 millionViewN/AView Earnings Details
8/3/2016Q2 2016($0.18)$0.03$25.24 million$39.00 millionViewN/AView Earnings Details
5/2/2016Q116($0.25)($0.45)$13.47 million$4.03 millionViewN/AView Earnings Details
3/8/2016Q415($0.15)$0.04$17.55 million$34.38 millionViewN/AView Earnings Details
11/23/2015Q3($0.08)$0.01$15.80 million$19.15 millionViewN/AView Earnings Details
8/10/2015Q215($0.01)($0.18)$1.00 million$9.90 millionViewN/AView Earnings Details
5/28/2015Q115($0.08)($39.97)$12.03 million$9.60 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aduro BioTech (NASDAQ:ADRO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aduro BioTech (NASDAQ ADRO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 46.44%
Insider Trading History for Aduro BioTech (NASDAQ:ADRO)
Institutional Ownership by Quarter for Aduro BioTech (NASDAQ:ADRO)

Aduro BioTech (NASDAQ ADRO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2018Blaine TemplemanInsiderSell2,000$8.15$16,300.0069,937View SEC Filing  
5/9/2018Stephen T IsaacsCEOSell40,000$8.01$320,400.00211,434View SEC Filing  
4/2/2018Stephen T IsaacsInsiderSell40,000$8.91$356,400.00245,746View SEC Filing  
3/9/2018Stephen T IsaacsInsiderSell72,051$8.48$610,992.48231,380View SEC Filing  
2/26/2018Elsas Andrea VanInsiderSell6,874$6.48$44,543.52216,669View SEC Filing  
1/5/2018Stephen T IsaacsInsiderSell7,949$7.95$63,194.55213,695View SEC Filing  
1/2/2018Gregory W SchaferCOOSell20,000$7.61$152,200.00190,745View SEC Filing  
12/18/2017Blaine TemplemanVPSell2,884$8.25$23,793.0069,937View SEC Filing  
12/15/2017Dirk G BrockstedtEVPSell65,223$8.11$528,958.53137,826View SEC Filing  
12/1/2017Dirk G BrockstedtEVPSell10,000$9.40$94,000.0077,674View SEC Filing  
12/1/2017Gregory W SchaferCOOSell20,000$9.34$186,800.00155,676View SEC Filing  
12/1/2017Jennifer LewVPSell6,600$9.46$62,436.0068,938View SEC Filing  
12/1/2017Stephen T IsaacsInsiderSell40,000$9.38$375,200.00213,921View SEC Filing  
11/17/2017Blaine TemplemanVPSell243$8.85$2,150.55View SEC Filing  
11/15/2017Jennifer LewInsiderSell6,600$8.95$59,070.0068,938View SEC Filing  
11/13/2017Dirk G BrockstedtEVPSell5,877$8.00$47,016.0075,533View SEC Filing  
11/13/2017Stephen T IsaacsInsiderSell19,800$7.97$157,806.00190,321View SEC Filing  
11/10/2017Dirk G BrockstedtEVPSell1,815$8.01$14,538.1575,533View SEC Filing  
11/10/2017Stephen T IsaacsCEOSell16,400$7.96$130,544.00190,321View SEC Filing  
11/7/2017Stephen T IsaacsInsiderSell20,200$7.98$161,196.00190,321View SEC Filing  
11/6/2017Dirk G BrockstedtEVPSell4,123$8.04$33,148.9277,841View SEC Filing  
11/6/2017Gregory W SchaferCOOSell20,000$7.97$159,400.00155,677View SEC Filing  
10/2/2017Dirk G BrockstedtEVPSell10,000$10.59$105,900.00View SEC Filing  
10/2/2017Gregory W SchaferCOOSell20,000$10.75$215,000.00View SEC Filing  
10/2/2017Jennifer LewInsiderSell6,600$10.61$70,026.00View SEC Filing  
10/2/2017Stephen T IsaacsCEOSell40,000$10.78$431,200.00213,921View SEC Filing  
9/18/2017Blaine TemplemanVPSell2,884$11.20$32,300.8058,834View SEC Filing  
9/13/2017Blaine TemplemanVPSell3,557$10.99$39,091.4365,275View SEC Filing  
9/13/2017Elsas Andrea VanInsiderSell4,922$10.99$54,092.78212,153View SEC Filing  
9/13/2017Gregory W SchaferCOOSell4,859$10.99$53,400.41153,604View SEC Filing  
9/1/2017Dirk G BrockstedtEVPSell10,000$11.69$116,900.0059,300View SEC Filing  
9/1/2017Gregory W SchaferCOOSell20,000$11.70$234,000.00131,645View SEC Filing  
9/1/2017Jennifer LewInsiderSell6,600$11.70$77,220.0049,195View SEC Filing  
8/11/2017Thomas W DubenskyInsiderSell50,000$11.38$569,000.0080,812View SEC Filing  
8/10/2017Thomas W DubenskyInsiderSell40,912$11.43$467,624.1680,812View SEC Filing  
8/8/2017Gregory W SchaferCOOSell40,000$12.17$486,800.00133,879View SEC Filing  
8/7/2017Dirk G BrockstedtEVPSell10,000$12.18$121,800.0059,300View SEC Filing  
8/7/2017Gregory W SchaferCOOSell25,811$12.17$314,119.87133,879View SEC Filing  
8/7/2017Jennifer LewInsiderSell6,600$12.17$80,322.0049,195View SEC Filing  
8/7/2017Stephen T IsaacsCEOSell40,000$12.19$487,600.00144,025View SEC Filing  
7/6/2017Thomas W DubenskyInsiderSell50,000$11.33$566,500.0051,700View SEC Filing  
7/5/2017Stephen T IsaacsInsiderSell40,000$11.06$442,400.00132,093View SEC Filing  
7/3/2017Dirk G BrockstedtEVPSell10,000$11.02$110,200.0053,956View SEC Filing  
7/3/2017Jennifer LewInsiderSell12,000$11.14$133,680.0054,595View SEC Filing  
6/28/2017Gregory W SchaferCOOSell40,000$11.26$450,400.00160,979View SEC Filing  
6/28/2017Jennifer LewInsiderSell12,000$11.19$134,280.0054,595View SEC Filing  
6/19/2017Stephen T IsaacsInsiderSell40,000$10.50$420,000.00125,486View SEC Filing  
6/5/2017Thomas W DubenskyInsiderSell144,301$10.03$1,447,339.03117,871View SEC Filing  
5/17/2017Blaine TemplemanVPSell1,648$9.65$15,903.20View SEC Filing  
5/17/2017Dirk G. BrockstedtEVPSell1,011$9.65$9,756.15View SEC Filing  
5/16/2017Stephen T. IsaacsCEOSell16,673$10.00$166,730.00View SEC Filing  
5/16/2017Stephen T. IsaacsinsiderSell27,273$10.01$273,002.73View SEC Filing  
5/15/2017Stephen T. IsaacsCEOSell10,600$10.01$106,106.00View SEC Filing  
5/12/2017Thomas W DubenskyInsiderSell5,699$9.92$56,534.0841,300View SEC Filing  
5/11/2017Dirk G BrockstedtEVPSell8,000$9.72$77,760.0057,300View SEC Filing  
4/3/2017Dirk G BrockstedtEVPSell8,000$10.71$85,680.0057,300View SEC Filing  
4/3/2017Stephen T IsaacsInsiderSell27,273$10.28$280,366.44129,473View SEC Filing  
3/13/2017Stephen T IsaacsInsiderSell27,273$11.35$309,548.55129,473View SEC Filing  
3/9/2017Dirk G BrockstedtEVPSell8,000$11.00$88,000.0057,300View SEC Filing  
3/9/2017Thomas W DubenskyInsiderSell25,000$10.96$274,000.0054,804View SEC Filing  
1/17/2017Dirk G BrockstedtEVPSell8,000$11.86$94,880.0057,300View SEC Filing  
1/11/2017Blaine TemplemanVPSell3,785$11.95$45,230.75View SEC Filing  
1/3/2017Stephen T IsaacsInsiderSell27,273$11.12$303,275.76119,896View SEC Filing  
12/1/2016Thomas W DubenskyInsiderSell25,000$10.94$273,500.0053,763View SEC Filing  
11/14/2016Ross HaghighatDirectorSell7,088$15.50$109,864.00View SEC Filing  
10/3/2016Stephen T IsaacsCEOSell27,273$12.67$345,548.91129,473View SEC Filing  
10/3/2016Thomas W DubenskyInsiderSell25,000$12.68$317,000.0055,424View SEC Filing  
9/19/2016Jennifer LewInsiderSell6,360$14.95$95,082.0048,955View SEC Filing  
9/1/2016Thomas W DubenskyInsiderSell25,000$14.03$350,750.0016,407View SEC Filing  
8/11/2016Thomas W DubenskyInsiderSell25,000$15.18$379,500.0012,500View SEC Filing  
7/5/2016Thomas W DubenskyInsiderSell25,000$11.61$290,250.0013,939View SEC Filing  
5/16/2016Thomas W. DubenskyInsiderSell905$8.20$7,421.00View SEC Filing  
1/11/2016Dirk G. BrockstedtVPSell22,000$21.77$478,940.0012,000View SEC Filing  
1/8/2016Gregory W. SchaferCOOSell20,000$23.58$471,600.0049,279View SEC Filing  
1/6/2016Jennifer LewVPSell5,242$25.71$134,771.826,200View SEC Filing  
1/5/2016Stephen T. IsaacsCEOSell25,000$26.31$657,750.0010,000View SEC Filing  
1/4/2016Thomas W. DubenskyinsiderSell15,000$26.37$395,550.00View SEC Filing  
12/7/2015Gregory W. SchaferCOOSell25,000$29.74$743,500.0034,279View SEC Filing  
12/3/2015Jennifer LewVPSell5,242$29.85$156,473.702,000View SEC Filing  
12/1/2015Stephen T. IsaacsCEOSell25,000$29.11$727,750.00View SEC Filing  
12/1/2015Thomas W. DubenskyinsiderSell30,000$29.27$878,100.00View SEC Filing  
11/18/2015Jennifer LewVPSell6,712$28.52$191,426.242,000View SEC Filing  
11/17/2015Gregory W. SchaferCOOSell26,470$28.15$745,130.5034,279View SEC Filing  
11/17/2015Thomas W. DubenskyinsiderSell31,470$28.27$889,656.90View SEC Filing  
11/16/2015Stephen T. IsaacsCEOSell25,000$27.54$688,500.00View SEC Filing  
4/20/2015Jennifer LewVPBuy2,000$17.00$34,000.00View SEC Filing  
4/20/2015Venture (Vi) Inves MorningsideMajor ShareholderBuy441,176$17.00$7,499,992.00View SEC Filing  
4/20/2015William Mariner GreenmanDirectorBuy3,000$17.00$51,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aduro BioTech (NASDAQ ADRO) News Headlines

Source:
DateHeadline
Cantor Fitzgerald Analysts Raise Earnings Estimates for Aduro BioTech Inc (ADRO)Cantor Fitzgerald Analysts Raise Earnings Estimates for Aduro BioTech Inc (ADRO)
www.americanbankingnews.com - May 24 at 9:19 AM
Aduro BioTech Inc (ADRO) Insider Blaine Templeman Sells 2,000 SharesAduro BioTech Inc (ADRO) Insider Blaine Templeman Sells 2,000 Shares
www.americanbankingnews.com - May 21 at 8:38 PM
Aduro BioTech Inc (ADRO) Expected to Announce Quarterly Sales of $3.75 MillionAduro BioTech Inc (ADRO) Expected to Announce Quarterly Sales of $3.75 Million
www.americanbankingnews.com - May 20 at 3:09 AM
Aduro Biotech (ADRO) Presents At Bank of America Merrill Lynch 2018 Healthcare Conference - SlideshowAduro Biotech (ADRO) Presents At Bank of America Merrill Lynch 2018 Healthcare Conference - Slideshow
seekingalpha.com - May 18 at 5:38 PM
 Brokerages Expect Aduro BioTech Inc (ADRO) Will Announce Earnings of -$0.33 Per Share Brokerages Expect Aduro BioTech Inc (ADRO) Will Announce Earnings of -$0.33 Per Share
www.americanbankingnews.com - May 18 at 11:25 AM
Aduro BioTech Inc (ADRO) Receives Average Rating of "Buy" from AnalystsAduro BioTech Inc (ADRO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 13 at 5:35 AM
Aduro BioTech (ADRO) Stock Rating Upgraded by BidaskClubAduro BioTech (ADRO) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - May 12 at 5:01 PM
Aduro BioTech Inc (ADRO) CEO Sells $320,400.00 in StockAduro BioTech Inc (ADRO) CEO Sells $320,400.00 in Stock
www.americanbankingnews.com - May 11 at 7:59 PM
Aduro Biotech to Present at the Bank of America Merrill Lynch 2018 Health Care ConferenceAduro Biotech to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 10 at 5:38 PM
Aduro BioTech Inc Forecasted to Earn Q2 2018 Earnings of ($0.33) Per Share (ADRO)Aduro BioTech Inc Forecasted to Earn Q2 2018 Earnings of ($0.33) Per Share (ADRO)
www.americanbankingnews.com - May 7 at 2:49 AM
Q2 2018 EPS Estimates for Aduro BioTech Inc Reduced by William Blair (ADRO)Q2 2018 EPS Estimates for Aduro BioTech Inc Reduced by William Blair (ADRO)
www.americanbankingnews.com - May 7 at 2:49 AM
Aduro BioTech (ADRO) Raised to Hold at BidaskClubAduro BioTech (ADRO) Raised to Hold at BidaskClub
www.americanbankingnews.com - May 5 at 1:07 AM
Aduro (ADRO) Q1 Loss Narrower Than Expected, Revenues BeatAduro (ADRO) Q1 Loss Narrower Than Expected, Revenues Beat
finance.yahoo.com - May 4 at 5:15 PM
Aduro BioTech (ADRO) Announces  Earnings ResultsAduro BioTech (ADRO) Announces Earnings Results
www.americanbankingnews.com - May 3 at 2:54 PM
Aduro BioTech (ADRO) Given a $10.00 Price Target at HC WainwrightAduro BioTech (ADRO) Given a $10.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 3 at 12:52 PM
Aduro Biotech: 1Q Earnings SnapshotAduro Biotech: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 8:30 AM
Aduro Biotech beats by $0.07, beats on revenueAduro Biotech beats by $0.07, beats on revenue
seekingalpha.com - May 2 at 5:23 PM
Aduro Biotech Reports First Quarter 2018 Financial ResultsAduro Biotech Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 2 at 5:23 PM
$3.88 Million in Sales Expected for Aduro BioTech Inc (ADRO) This Quarter$3.88 Million in Sales Expected for Aduro BioTech Inc (ADRO) This Quarter
www.americanbankingnews.com - May 2 at 1:04 AM
 Brokerages Anticipate Aduro BioTech Inc (ADRO) to Post -$0.30 Earnings Per Share Brokerages Anticipate Aduro BioTech Inc (ADRO) to Post -$0.30 Earnings Per Share
www.americanbankingnews.com - April 30 at 11:14 PM
Vaccine Market Size Expected to Surpass $77 Billion at 10.3% CAGR by 2024 | Million InsightsVaccine Market Size Expected to Surpass $77 Billion at 10.3% CAGR by 2024 | Million Insights
www.prnewswire.com - April 30 at 5:03 PM
Aduro BioTech (ADRO) PT Set at $10.00 by HC WainwrightAduro BioTech (ADRO) PT Set at $10.00 by HC Wainwright
www.americanbankingnews.com - April 27 at 10:30 AM
Aduro Biotech Presents Early Observations From its Personalized Neoantigen-based pLADD Therapy Clinical Study at ...Aduro Biotech Presents Early Observations From its Personalized Neoantigen-based pLADD Therapy Clinical Study at ...
globenewswire.com - April 26 at 8:30 AM
Aduro Biotech Presents Early Observations From its Personalized Neoantigen-based pLADD Therapy Clinical Study at European Neoantigen SummitAduro Biotech Presents Early Observations From its Personalized Neoantigen-based pLADD Therapy Clinical Study at European Neoantigen Summit
finance.yahoo.com - April 26 at 8:30 AM
Aduro BioTech (ADRO) Downgraded by BidaskClubAduro BioTech (ADRO) Downgraded by BidaskClub
www.americanbankingnews.com - April 21 at 7:06 AM
Research Analysts Issue Forecasts for Aduro BioTech Incs FY2018 Earnings (ADRO)Research Analysts Issue Forecasts for Aduro BioTech Inc's FY2018 Earnings (ADRO)
www.americanbankingnews.com - April 19 at 7:14 AM
Aduro BioTech Inc (ADRO) Given Average Recommendation of "Buy" by BrokeragesAduro BioTech Inc (ADRO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 18 at 5:28 AM
Cowen Begins Coverage on Aduro BioTech (ADRO)Cowen Begins Coverage on Aduro BioTech (ADRO)
www.americanbankingnews.com - April 17 at 7:01 PM
Aduro Biotech Highlights Preclinical Data for Three Programs Reported at the American Association for Cancer Research Annual MeetingAduro Biotech Highlights Preclinical Data for Three Programs Reported at the American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 17 at 5:42 PM
Aduro BioTech (ADRO) Rating Increased to Buy at BidaskClubAduro BioTech (ADRO) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - April 16 at 12:02 PM
Aduro BioTech Inc (ADRO) Expected to Announce Quarterly Sales of $3.88 MillionAduro BioTech Inc (ADRO) Expected to Announce Quarterly Sales of $3.88 Million
www.americanbankingnews.com - April 16 at 5:36 AM
Aduro BioTech (ADRO) Downgraded by Zacks Investment ResearchAduro BioTech (ADRO) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 14 at 10:19 AM
Aduro BioTech (ADRO) Stock Rating Lowered by BidaskClubAduro BioTech (ADRO) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 8:31 AM
Zacks: Analysts Expect Aduro BioTech Inc (ADRO) to Post -$0.30 Earnings Per ShareZacks: Analysts Expect Aduro BioTech Inc (ADRO) to Post -$0.30 Earnings Per Share
www.americanbankingnews.com - April 14 at 1:08 AM
HC Wainwright Analysts Give Aduro BioTech (ADRO) a $18.00 Price TargetHC Wainwright Analysts Give Aduro BioTech (ADRO) a $18.00 Price Target
www.americanbankingnews.com - April 13 at 7:13 PM
BidaskClub Downgrades Aduro BioTech (ADRO) to SellBidaskClub Downgrades Aduro BioTech (ADRO) to Sell
www.americanbankingnews.com - April 12 at 11:22 PM
Aduro Biotech (ADRO) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowAduro Biotech (ADRO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 5:17 PM
HC Wainwright Reiterates $18.00 Price Target for Aduro BioTech (ADRO)HC Wainwright Reiterates $18.00 Price Target for Aduro BioTech (ADRO)
www.americanbankingnews.com - April 6 at 9:50 PM
Aduro BioTech (ADRO) Downgraded by ValuEngineAduro BioTech (ADRO) Downgraded by ValuEngine
www.americanbankingnews.com - April 6 at 11:39 AM
Aduro BioTech (ADRO) Lowered to Buy at BidaskClubAduro BioTech (ADRO) Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 6 at 11:17 AM
Key events next week - healthcareKey events next week - healthcare
seekingalpha.com - April 6 at 8:47 AM
Aduro BioTech Inc (ADRO) Insider Stephen T. Isaacs Sells 40,000 SharesAduro BioTech Inc (ADRO) Insider Stephen T. Isaacs Sells 40,000 Shares
www.americanbankingnews.com - April 4 at 10:56 PM
Aduro Biotech to Present at the HC Wainwright Annual Global Life Sciences ConferenceAduro Biotech to Present at the HC Wainwright Annual Global Life Sciences Conference
globenewswire.com - April 2 at 5:14 PM
Aduro Biotech to Present at the H.C. Wainwright Annual Global Life Sciences ConferenceAduro Biotech to Present at the H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - April 2 at 5:14 PM
Aduro BioTech (ADRO) Given a $18.00 Price Target by HC Wainwright AnalystsAduro BioTech (ADRO) Given a $18.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 2 at 2:04 PM
Aduro BioTech (ADRO) Lifted to Strong-Buy at BidaskClubAduro BioTech (ADRO) Lifted to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 29 at 11:16 AM
 Brokerages Anticipate Aduro BioTech Inc (ADRO) to Announce -$0.30 EPS Brokerages Anticipate Aduro BioTech Inc (ADRO) to Announce -$0.30 EPS
www.americanbankingnews.com - March 28 at 1:20 AM
Aduro BioTech (ADRO) Upgraded by BidaskClub to SellAduro BioTech (ADRO) Upgraded by BidaskClub to Sell
www.americanbankingnews.com - March 27 at 12:06 AM
Aduro BioTech (ADRO) Rating Lowered to Strong Sell at ValuEngineAduro BioTech (ADRO) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - March 25 at 9:16 PM
Aduro BioTech Inc (ADRO) Given Consensus Recommendation of "Hold" by BrokeragesAduro BioTech Inc (ADRO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 24 at 8:10 AM

SEC Filings

Aduro BioTech (NASDAQ:ADRO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aduro BioTech (NASDAQ:ADRO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aduro BioTech (NASDAQ ADRO) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.